227 related articles for article (PubMed ID: 14976049)
1. SOCS1 and SHP1 hypermethylation in multiple myeloma: implications for epigenetic activation of the Jak/STAT pathway.
Chim CS; Fung TK; Cheung WC; Liang R; Kwong YL
Blood; 2004 Jun; 103(12):4630-5. PubMed ID: 14976049
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic dysregulation of the Jak/STAT pathway by frequent aberrant methylation of SHP1 but not SOCS1 in acute leukaemias.
Chim CS; Wong AS; Kwong YL
Ann Hematol; 2004 Aug; 83(8):527-32. PubMed ID: 14762685
[TBL] [Abstract][Full Text] [Related]
3. Down-regulation of SHP1 and up-regulation of negative regulators of JAK/STAT signaling in HTLV-1 transformed cell lines and freshly transformed human peripheral blood CD4+ T-cells.
Cheng J; Zhang D; Zhou C; Marasco WA
Leuk Res; 2004 Jan; 28(1):71-82. PubMed ID: 14630083
[TBL] [Abstract][Full Text] [Related]
4. SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway.
Chim CS; Wong KY; Loong F; Srivastava G
Leukemia; 2004 Feb; 18(2):356-8. PubMed ID: 14614518
[No Abstract] [Full Text] [Related]
5. Methylation profiling of SOCS1, SOCS2, SOCS3, CISH and SHP1 in Philadelphia-negative myeloproliferative neoplasm.
Zhang MY; Fung TK; Chen FY; Chim CS
J Cell Mol Med; 2013 Oct; 17(10):1282-90. PubMed ID: 24131863
[TBL] [Abstract][Full Text] [Related]
6. SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma.
Galm O; Yoshikawa H; Esteller M; Osieka R; Herman JG
Blood; 2003 Apr; 101(7):2784-8. PubMed ID: 12456503
[TBL] [Abstract][Full Text] [Related]
7. Control mechanism of JAK/STAT signal transduction pathway.
Yamada S; Shiono S; Joo A; Yoshimura A
FEBS Lett; 2003 Jan; 534(1-3):190-6. PubMed ID: 12527385
[TBL] [Abstract][Full Text] [Related]
8. Constitutional activation of IL-6-mediated JAK/STAT pathway through hypermethylation of SOCS-1 in human gastric cancer cell line.
To KF; Chan MW; Leung WK; Ng EK; Yu J; Bai AH; Lo AW; Chu SH; Tong JH; Lo KW; Sung JJ; Chan FK
Br J Cancer; 2004 Oct; 91(7):1335-41. PubMed ID: 15354212
[TBL] [Abstract][Full Text] [Related]
9. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
[TBL] [Abstract][Full Text] [Related]
10. Methylated alteration of SHP1 complements mutation of JAK2 tyrosine kinase in patients with myeloproliferative neoplasm.
Yang JJ; Chen H; Zheng XQ; Li HY; Wu JB; Tang LY; Gao SM
Asian Pac J Cancer Prev; 2015; 16(6):2219-25. PubMed ID: 25824741
[TBL] [Abstract][Full Text] [Related]
11. Protein tyrosine phosphatase epsilonC selectively inhibits interleukin-6- and interleukin- 10-induced JAK-STAT signaling.
Tanuma N; Shima H; Nakamura K; Kikuchi K
Blood; 2001 Nov; 98(10):3030-4. PubMed ID: 11698287
[TBL] [Abstract][Full Text] [Related]
12. Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors.
Reddy J; Shivapurkar N; Takahashi T; Parikh G; Stastny V; Echebiri C; Crumrine K; Zöchbauer-Müller S; Drach J; Zheng Y; Feng Z; Kroft SH; McKenna RW; Gazdar AF
Oncogene; 2005 Jan; 24(4):732-6. PubMed ID: 15580314
[TBL] [Abstract][Full Text] [Related]
13. Involvement of JAK/STAT (Janus kinase/signal transducer and activator of transcription) in the thyrotropin signaling pathway.
Park ES; Kim H; Suh JM; Park SJ; You SH; Chung HK; Lee KW; Kwon OY; Cho BY; Kim YK; Ro HK; Chung J; Shong M
Mol Endocrinol; 2000 May; 14(5):662-70. PubMed ID: 10809230
[TBL] [Abstract][Full Text] [Related]
14. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
[TBL] [Abstract][Full Text] [Related]
15. Modulation of Janus kinase 2 by cisplatin in cancer cells.
Song H; Sondak VK; Barber DL; Reid TJ; Lin J
Int J Oncol; 2004 Apr; 24(4):1017-26. PubMed ID: 15010843
[TBL] [Abstract][Full Text] [Related]
16. As
Wu D; Dong W; Fang K; Wang M
Technol Cancer Res Treat; 2019; 18():1533033819896806. PubMed ID: 31868118
[TBL] [Abstract][Full Text] [Related]
17. A mutant form of JAB/SOCS1 augments the cytokine-induced JAK/STAT pathway by accelerating degradation of wild-type JAB/CIS family proteins through the SOCS-box.
Hanada T; Yoshida T; Kinjyo I; Minoguchi S; Yasukawa H; Kato S; Mimata H; Nomura Y; Seki Y; Kubo M; Yoshimura A
J Biol Chem; 2001 Nov; 276(44):40746-54. PubMed ID: 11522790
[TBL] [Abstract][Full Text] [Related]
18. Cytokine signaling in 2002: new surprises in the Jak/Stat pathway.
O'Shea JJ; Gadina M; Schreiber RD
Cell; 2002 Apr; 109 Suppl():S121-31. PubMed ID: 11983158
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic modification of SOCS-1 differentially regulates STAT3 activation in response to interleukin-6 receptor and epidermal growth factor receptor signaling through JAK and/or MEK in head and neck squamous cell carcinomas.
Lee TL; Yeh J; Van Waes C; Chen Z
Mol Cancer Ther; 2006 Jan; 5(1):8-19. PubMed ID: 16432158
[TBL] [Abstract][Full Text] [Related]
20. The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-STAT activation.
Iwamoto T; Senga T; Naito Y; Matsuda S; Miyake Y; Yoshimura A; Hamaguchi M
Oncogene; 2000 Sep; 19(41):4795-801. PubMed ID: 11032030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
